ATCC's High Containment Facility Renovations in Support of NIAID and Pandemic Preparedness

项目摘要： 该项目旨在改造美国国家航空航天局的高密封设施（HCF）。 弗吉尼亚州马纳萨斯的典型培养物保藏中心（ATCC）。ATCC的7，500平方英尺生物防护设施 在NIAID的资助下于2007年建成，一直致力于开发传染性 快速推进诊断、疫苗和治疗所需的疾病菌株和试剂 对抗重点病原体自2003年以来，ATCC与NIAID合作，集中并提供 通过生物防御和新出现的感染资源（BEI）提供关键的科学资源 资源）程序。NIAID建立了BEI资源，以提供全球研究 提供试剂、工具和信息的社区，用于研究A、B和C类优先级 病原体、新出现的传染病病原体和其他微生物材料， 人体健康在过去的18年里，ATCC已经为超过1，360，000名 119个国家3,740个机构的14,000名研究人员，涉及500多种人类病原体 在NIAID的优先投资组合。在此期间，BEI Resources为以下项目提供了关键材料： 重大疾病爆发，包括H1N1、MERS、埃博拉和寨卡病毒。在过去的两年里，ATCC 迅速创造了690多种SARS-CoV-2产品;收购、生产和认证 超过165种SARS-CoV-2库存，用于一般研究和挑战研究;以及 向70多个国家的2，800多名研究人员运送了86，000多份研究试剂 发展对策和基础研究。BEI提供的材料 自2020年2月以来，已有1，800多篇SARS-CoV-2出版物引用了资源。 此外，ATCC还促进了NIAID项目之间的合作和伙伴关系， 外部工作组共享资源、信息和数据，以加速发现， 协调应对和防备大流行病的科学方法。 ATCC的高封闭设施设有BSL-3和选择剂所必需的实验室 传染病研究、产品开发和大规模试剂生产， 研究社区。本提案旨在改造和升级暖通空调，净化， 和安全系统。翻修还包括对固定设备和内部的升级 在设施中完成。翻修将使该设施现代化，供40名博士使用。ATCC 科学家、合作者和实验室支持人员。开发的产品和服务， 该设施每年将支持全球数千名科学家准备和应对 流行病ATCC正在寻求与NIAID合作的机会， 该设施一直是国家应对和准备大流行病的基础。

Project Summary: The proposed project aims to renovate ATCC's High Containment Facility (HCF) at the American Type Culture Collection (ATCC) in Manassas, Virginia. ATCC's 7,500 ft2 biocontainment facility was built in 2007 with funding from NIAID and has been dedicated to developing infectious disease strains and reagents needed to rapidly advance diagnostics, vaccines, and therapeutics against priority pathogens. Since 2003, ATCC has partnered with NIAID to centralize and provide critical scientific resources through the Biodefense and Emerging Infections Resources (BEI Resources) program. The NIAID established BEI Resources to provide the global research community with reagents, tools, and information for studying Category A, B, and C priority pathogens, emerging infectious disease agents, and other microbiological materials relevant to human health. Over the past 18 years, ATCC has provided over 1,360,000 reagents to over 14,000 investigators at 3,740 institutions in 119 countries spanning over 500 human pathogens in NIAID's priority portfolio. During this period, BEI Resources has provided critical materials for vital disease outbreaks, including H1N1, MERS, Ebola, and Zika. Over the past two years, ATCC has rapidly created more than 690 SARS-CoV-2 products; acquired, produced, and authenticated more than 165 stocks of SARS-CoV-2 for both general research and challenge studies; and shipped more than 86,000 research reagents to over 2,800 researchers in more than 70 countries for the development of countermeasures and basic research. The material provided by BEI Resources has been cited in more than 1,800 SARS-CoV-2 publications since February of 2020. In addition, ATCC has fostered collaboration and partnerships across NIAID programs and external working groups to share resources, information, and data to accelerate discoveries and harmonize scientific approaches for pandemic response and preparedness. ATCC's high containment facility houses laboratories essential for BSL-3 and Select Agent infectious disease research, product development, and large-scale reagent production for the research community. This proposal aims to renovate and upgrade the HVAC, decontamination, and security systems. The renovations also include upgrades to fixed equipment and interior finishing in the facility. The renovations will modernize the facility for use by 40 Ph.D. ATCC scientists, collaborators, and laboratory support staff. The products and services developed in the facility will support thousands of scientists globally each year to prepare and respond to pandemics. ATCC is seeking this opportunity for engagement with the NIAID to invest in this facility which has been foundational for the nation's pandemic response and preparedness.